AdasuveTreatment for Agitation, Schizophrenia, Bipolar Disorder
Update: Adasuve (loxapine) Now FDA Approved - December 21, 2012
Alexza Announces Adasuve Staccato (Loxapine) PDUFA Goal Date of February 4, 2012
MOUNTAIN VIEW, Calif., Aug. 19, 2011 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. announced today that the U.S. Food & Drug Administration (FDA) has accepted the Adasuve New Drug Application (NDA) as a complete, class 2 response to the FDA's action letter, with an indicated Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012. On August 4, 2011, Alexza resubmitted the Adasuve NDA, which seeks marketing approval for the rapid treatment of agitation in adults with schizophrenia or bipolar disorder.
Alexza's NDA is based on a comprehensive clinical development program including two positive Phase 3 clinical trials. In addition to the data from the original NDA and supplemental analyses of some of these data, the Adasuve resubmission contains new data from a successfully completed human factors study, stability data from new production batches manufactured in late 2010, updated manufacturing and controls sections addressing findings from the Company's Pre-Approval Inspection, and updated draft labeling and a comprehensive Risk Evaluation and Mitigation Strategy (REMS) proposal.
"If approved, Adasuve would be the first drug marketed based on the novel Staccato technology platform," stated Thomas B. King, President and Chief Executive Officer of Alexza. "We believe Adasuve can offer physicians and patients a new therapeutic option, which combines rapid onset of action and reliability of medication delivery in a non-invasive formulation that is easy to administer. These are the key attributes outlined by the American Association for Emergency Psychiatry for the treatment of behavioral emergencies."
Agitation can occur in many people suffering from major psychiatric disorders, including schizophrenia, which affects approximately 2.4 million adults in the United States, and bipolar disorder, which affects approximately 5.7 million adults in the United States. More than 90% of these people will experience agitation in their lifetime. Agitation generally escalates over a short period of time with patients initially feeling uncomfortable, tense and restless. As the agitation intensifies, their behavior appears more noticeable to others as they become threatening and potentially violent, especially if the agitation is not treated. Agitation episodes are currently most often treated with antipsychotics and / or benzodiazepines in oral or intramuscular injection preparations. However, there are no non-invasive therapies that work within 30 minutes to help agitated patients in need of treatment.
Staccato loxapine and the Staccato System
Adasuve is an anti-agitation product candidate that combines Alexza's proprietary Staccato system with loxapine, an antipsychotic currently available in the U.S. as an oral formulation for the management of schizophrenia. The Staccato system is a hand-held, single-dose inhaler that delivers a medication comparable to intravenous administration, but with greater ease, patient comfort and convenience. In clinical studies, Adasuve has shown an onset of effect in 10 minutes of dosing, which is the first time point measured in the Phase 3 clinical studies. The Adasuve NDA contains efficacy and safety data from more than 1,600 patients and subjects who have been studied in thirteen different clinical trials.
About Alexza Pharmaceuticals, Inc.
Alexza is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.
Adasuve (Staccato loxapine), Alexza's lead program, is being developed for the rapid treatment of agitation in adults with schizophrenia or bipolar disorder. Alexza has completed and announced positive results from both of its Adasuve Phase 3 clinical trials and initially submitted the Adasuve NDA in December 2009. In October 2010, the Company received a Complete Response Letter from the FDA regarding the application. The Company completed an end-of-review meeting with the FDA in late December 2010 and a Risk Evaluation and Mitigation Strategy (REMS) guidance meeting with the FDA in April 2011. The Adasuve NDA was resubmitted on August 4, 2011, and has a Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012. The FDA has indicated that it will likely present the Adasuve application to an Advisory Committee during the review period. The Company also plans to file the Adasuve Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in the second half of 2011.
Safe Harbor Statement
This press release contains forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the adequacy of the Company's capital to support the Company's operations, the potential of the Company's Adasuve NDA resubmission to adequately address the issues in the CRL, the timing of the FDA's review of the NDA and the eventual prospects that Adasuve will be approved for marketing
The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements . These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission . Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise .
SOURCE Alexza Pharmaceuticals, Inc.
Posted: August 2011
- FDA Approves Adasuve (loxapine) Inhalation Powder for the Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I Disorder in Adults - December 21, 2012
- Alexza Announces Adasuve (Staccato Loxapine) PDUFA Goal Date of December 21, 2012 - July 6, 2012
- Alexza Receives Complete Response Letter for Adasuve NDA - May 3, 2012
- Alexza Announces Extension of the Adasuve PDUFA Goal Date by Three Months - January 23, 2012
- Alexza Announces the Adasuve (Staccato Loxapine) PDAC Meeting Date of December 12, 2011 - November 6, 2011
- Alexza Announces Resubmission of AZ-004 (Staccato Loxapine) NDA - August 5, 2011
- Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato Loxapine) NDA - January 18, 2011
- Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato Loxapine) - December 7, 2010
- Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato Loxapine) NDA - October 11, 2010
- Alexza Announces AZ-004 (Staccato Loxapine) PDUFA Goal Date of October 11, 2010 - February 18, 2010
- Biovail Enters into License and Collaboration Agreement with Alexza for AZ-004 - February 10, 2010
- Alexza Announces Submission of AZ-004 (Staccato Loxapine) NDA - December 15, 2009